Adjunctive Cariprazine in Patients With Major Depressive Disorder: Post Hoc Analysis of Efficacy by Baseline Antidepressant Response
Sign Up to like & getrecommendations! Published in 2023 at "CNS Spectrums"
DOI: 10.1017/s1092852923001797
Abstract: Abstract Introduction Patients with major depressive disorder (MDD) often have inadequate response to antidepressant treatment (ADT) requiring augmentation with other treatments. Cariprazine is a D3-preferring D3/D2 and serotonin 5-HT1A receptor partial agonist approved to treat… read more here.
Keywords: baseline; adt; cariprazine adt; placebo ... See more keywords
Incidence and Characteristics of Akathisia with Adjunctive Cariprazine Treatment in Patients with Major Depressive Disorder
Sign Up to like & getrecommendations! Published in 2024 at "CNS Spectrums"
DOI: 10.1017/s1092852924001603
Abstract: Purpose Akathisia is a common adverse effect associated with use of dopamine receptor blocking agents.1,2 Symptoms of akathisia, in severe cases, may lead to discontinuation of treatment. Cariprazine is a dopamine D3-preferring D3/D2 receptor partial… read more here.
Keywords: adt; cariprazine adt; placebo; akathisia ... See more keywords